Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en
SciELO
Similares en Google
Compartir
Urología Colombiana
versión On-line ISSN 2027-0119
Resumen
MANNEH-KOPP, Ray et al. Disease burden and treatment choice for metastatic hormone-sensitive prostate cancer in Colombia. Urol. Colomb. [online]. 2025, vol.34, n.1, pp.33-43. Epub 31-Jul-2025. ISSN 2027-0119. https://doi.org/10.24875/ruc.24000051.
Objective:
This literature review seeks to understand the landscape of this disease in Colombia (epidemiology, disease burden, diagnosis, and treatment).
Method:
An extensive search for published evidence was carried out, with no date or language limit, in the PUBMED, EMBASE, LILACS, and Scielo databases, gray literature, and administrative databases. The evaluation and selection of studies were carried out by two independent evaluators.
Results:
A total of 1574 references were identified from the PubMed (n = 630), Embase (n = 575), Cochrane Library (n = 335), Scielo (n = 6), and Lilacs (n = 25) databases, and three references were identified by manual search. After removing duplicates, 1157 references were obtained. A total of 921 references were excluded after reading the title and abstract. Two hundred and thirty-six full-text manuscripts were evaluated, and 87 were selected for information extraction. In addition, information was extracted from administrative databases and other sources that reported epidemiological data and treatment patterns of metastatic hormone-sensitive prostate cancer (mHSPC) in Colombia.
Conclusions:
Information regarding the burden, diagnosis, and treatment of mHSPC in Colombia is scarce. In general, the disease burden of mHSPC is underestimated and is of great interest due to its clinical and economic impact. Treatment intensification is implemented in most cases in the country; however, it is mainly performed with chemotherapy. The panorama described invites us to strengthen interventions for timely access and education to physicians in the appropriate treatment of this condition.
Palabras clave : Prostatic neoplasms; Hormone-sensitive prostate cancer; Novel hormonal therapy; Systemic therapy.












